会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Method of Diagnosing Pancreatic Cancer with the Use of N-Binding Type Sugar Chains
    • 使用N-结合型糖链诊断胰腺癌的方法
    • US20110065141A1
    • 2011-03-17
    • US12991340
    • 2009-05-08
    • Tokuzo AraoKazuko MatsumotoKazuto NishioHiroki SakamotoMasayuki KitanoMasatoshi Kudo
    • Tokuzo AraoKazuko MatsumotoKazuto NishioHiroki SakamotoMasayuki KitanoMasatoshi Kudo
    • C12Q1/37C12Q1/34
    • G01N33/57438Y10T436/24
    • The present invention is to provide a novel marker for diagnosing pancreatic cancer, a method for determining if a subject has pancreatic cancer utilizing the marker, etc. The present inventors collected blood from patients of 78 cases in total including patients of 24 cases with pancreaticobiliary-duct benign disorder (16 gallstone cases and 8 pancreatitis cases) and patients of 54 cases with pancreatic cancer, and mass spectrometry was performed on N-linked sugar chains in plasma. From the 74 mass-spectrometric peaks detected, 65 sugar chains were extracted based on the results of PAM analysis. These extracted sugar chains were then used to predict pancreatic cancer or pancreaticobiliary-duct benign disorder, to correctly diagnose 74% cases. Further, a T-test was performed between the two groups, the group of pancreaticobiliary-duct benign disorder and the group of pancreatic cancer, which identified two sugar chains, the sugar chain of m/z 3031 and the sugar chain of m/z 2362, as sugar chains demonstrating significant difference (p
    • 本发明提供一种用于诊断胰腺癌的新型标记物,用于确定受试者是否使用标记物的胰腺癌的方法等。本发明人从78例患者中收集了总共包括24例胰腺胆管癌患者的血液, 膀胱良性疾病(16例胆囊病例和8例胰腺炎病例)和54例胰腺癌患者,并对血浆中的N链糖链进行质谱分析。 根据PAM分析结果,从检测到的74个质谱峰中提取出65个糖链。 然后将这些提取的糖链用于预测胰腺癌或胰胆管良性疾病,以正确诊断74%的病例。 此外,在两组之间进行T检验,即胰胆管良性病变组和胰腺癌组,鉴定了两条糖链,m / z 3031的糖链和m / z的糖链 2362,由于糖链显示出显着性差异(p <0.05),并且两组之间的表达水平呈现2倍或更大的差异。 使用这些糖链的正确检测率用六个分类器计算,所有这些分类器都得到约70%的正确检测结果。